Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | NR2F2 | P24468 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17406900 | 0.87 | MEN1 (0.76) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17406918 | 0.86 | KMT2A (0.75) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL4362841 | 0.84 | KDM4E (1.00) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL8076506 | 0.84 | MEN1 (0.72) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17406915 | 0.84 | MEN1 (0.71) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL3157350 | 0.82 | MEN1 (1.00) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17406922 | 0.80 | MEN1 (0.66) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL8084587 | 0.79 | KMT2A (0.67) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL17620472 | 0.78 | MEN1 (0.65) | MEN1KMT2ANR2F2KDM4ETSHR | |
| SCHEMBL8076523 | 0.77 | MEN1 (0.64) | MEN1KMT2ANR2F2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | KCL THERAPEUTICS, INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | Zander Biologics, Inc (US) | 2022-07-05 | — | — | US | disclosed |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | KCL THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | KCL THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | disclosed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | disclosed |
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981968-B2 | Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders | NORTHWESTERN UNIVERSITY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2041137-A2 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1889847-A1 | Pyrrolopyrimidines for pharmaceutical compositions | DeveloGen Aktiengesellschaft (DE) | 2008-02-20 | — | — | EP | disclosed |
| EP-1889847-A1 | Pyrrolopyrimidines for pharmaceutical compositions | DeveloGen Aktiengesellschaft (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006547-A2 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006547-A2 | PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| US-6096749-A | ANTITUMOR, EPIDERMAL GROWTH FACTOR | NOVARTIS CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5686457-A | FOR TREATING A TUMOR OR PSORIASIS | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682027-B1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA GEIGY AG (CH) | 1997-10-15 | — | — | EP | disclosed |
| CN-1128263-A | Pyrrolopyrimidine derivatives having pharmacological activity | CIBA GEIGY AG (CH) | 1996-08-07 | — | — | CN | disclosed |
| EP-0682027-A1 | Pyrrolopyrimidine derivatives with antiproliferative action | CIBA-GEIGY AG (CH) | 1995-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | TRPV1, P2RX3, P2RX7 | MEN1 4876/4885KMT2A 3460/4885NR2F2 3344/4885 |
| US-11241427-B2 | Small molecule modulators of NR2F6 activity | NR2F2, NR2E3, NR2C2 | MEN1 4656/4885KMT2A 741/4885NR2F2 1/4885 |
| US-20220249436-A1 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | NR4A2, NR2C2, NR0B2 | MEN1 3917/4885KMT2A 999/4885NR2F2 4/4885 |
| US-20160002252-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | DPYD, TYMP, TYMS | MEN1 3694/4885KMT2A 2515/4885NR2F2 1980/4885 |
| US-11324719-B2 | Small molecule agonists and antagonists of NR2F6 activity in humans | NR4A2, NR2C2, NR0B2 | MEN1 3917/4885KMT2A 999/4885NR2F2 4/4885 |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | TRPV1, P2RX3, P2RX4 | MEN1 4866/4885KMT2A 3486/4885NR2F2 3289/4885 |
| US-11377442-B2 | Small molecule agonists and antagonists of NR2F6 activity | NR4A2, NR2C2, NR2F2 | MEN1 4260/4885KMT2A 968/4885NR2F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.